2
NBIX icon

2Xideas’s Neurocrine Biosciences NBIX Stock Holding History

2Xideas’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Buy
16,763
+6,412
+62% +$951K 1.22% 18
2026
Q1 		$1.36M Sell
10,351
-19,037
-65% -$2.53M 0.53% 40
2025
Q4 		$4.17M Sell
29,388
-21,409
-42% -$3.1M 1.17% 25
2025
Q3 		$7.13M Sell
50,797
-17,016
-25% -$2.31M 1.51% 18
2025
Q2 		$8.52M Sell
67,813
-4,696
-6% -$539K 1.47% 18
2025
Q1 		$8.02M Sell
72,509
-36,509
-33% -$4.62M 1.22% 31
2024
Q4 		$14.9M Buy
+109,018
New +$13.5M 1.99% 12

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

2Xideas's NBIX Position: Q2 2026 in Review

2Xideas increased its Neurocrine Biosciences (NBIX) stake by 62% in Q2 2026, buying an estimated $951K and bringing the position to 16,763 shares worth $2.83M. The position accounts for 1.22% of the portfolio, ranked #18.

2Xideas first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.9M in Q4 2024. 782 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • 2Xideas held 16,763 shares of Neurocrine Biosciences worth $2.83M as of Q2 2026.
  • 2Xideas bought 6,412 Neurocrine Biosciences shares in Q2 2026, an estimated $951K.
  • Neurocrine Biosciences made up 1.22% of 2Xideas's portfolio in Q2 2026, its #18 holding.
  • 2Xideas first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 2Xideas's Neurocrine Biosciences position peaked at $14.9M in Q4 2024.
  • 782 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on 2Xideas's 13F filing for Q2 2026, filed 14 Aug 2026.